NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSA™ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products […]
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology Orlando, FL – September 20, 2023 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,759,431 for Nutriband’s proprietary AVERSA™ abuse deterrent technology utilizing […]
Nutriband Inc. Signs Exclusive License Agreement with RAMBAM Hospital Group for its Closed System Transfer Device
Orlando, FL – December 15, 2020 – Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it signed an exclusive license agreement with RAMBAM Med Tech Ltd, a Division of the RAMBAM Hospital, the largest medical center in Northern Israel, for its Closed System Transfer Device designed to liquify drugs for patients who cannot swallow […]
Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its ‘Abuse and Misuse Deterrent Transdermal System’ Patent
Orlando, FL – December 10, 2020 – Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the “Company”) has received a notice of allowance from the Korean Intellectual Property Office (KIPO) for the ‘Abuse and Misuse Deterrent Transdermal Systems’ patent application filed by its clinical subsidiary 4P Therapeutics. The patent underpins 4p Therapeutics’ abuse deterrent fentanyl […]
NUTRIBAND INC. SIGNS ACQUISITION AGREEMENT OF CARMEL BIOSCIENCES AND FDA APPROVED PREXXARTAN™
Orlando, Fla. – Sept 26, 2018 – Nutriband Inc. (OTCQB: NTRB), is pleased to announce it has signed the definitive acquisition agreement to acquire Carmel Biosciences, Inc. The acquisition is expected to be valued at approximately $2,700,000 and will be paid in company stock in the amount of 350,000 restricted common shares. According to […]
Nutriband Inc. (OTCQB: NTRB) to Host Investor Webinar to Discuss Acquisition of 4P Therapeutics Inc. & Other Important Recent Developments
ORLANDO, Fla., Aug. 23, 2018 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a pharmaceutical company developing and commercializing a portfolio of prescription pharmaceuticals, OTC’s and consumer products based around the science of transdermal/topical technologies, announced today that Gareth Sheridan, CEO, will host an audio and video webinar, slide presentation and live Q & A session for […]
Nutriband Inc. Announces the Appointment of Larry Dillaha, MD as Chief Medical Officer and to Advisory Board
ORLANDO, Fla., Aug. 2, 2018 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB) announced the appointment of Larry Dillaha, MD as chief medical officer and as a member of its Pharmaceutical Advisory Board. Dr. Dillaha brings nearly 20 years of pharmaceutical industry experience to Nutriband. Prior to joining Nutriband, he was chief executive officer of Repros […]
